Althera has developed an innovative cancer treatment based on diffusing alpha-emitting radiotherapy (DART) technology.
Israeli start-up Althera Medical Ltd. today announced that it closed a $1.5 million first financing round. ProMed Capital Group of the US led the round, joined by private US and UK investors. ProMed partners Leonard Gordon and Dr. Jacob Dagan will join Althera’s board.
Althera chairman and CEO Dr. Gideon Shichman, chief scientist Prof. Yona Keisari, and CTO Prof. Itzhak Kelson founded the company in 2005. IVC Online says the company has five employees.
Althera has developed an innovative cancer treatment based on diffusing alpha-emitting radiotherapy (DART) technology. DART uses alpha particles to destroy tumors. Although the medical world has known for years that alpha particles are effective, there has been no way to target them to cancerous cells. Althera has apparently solved the problem. The company’s treatment can be applied to lung, brain and neck, breast, pelvic, rectum and pancreatic cancers.
Published by Globes [online], Israel business news - www.globes.co.il - on October 10, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006